Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 15;12:6286. doi: 10.1038/s41598-022-10139-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Schematic overview of [⁸⁹Zr]Zr-N-sucDf-NNV003 anti-CD37 PET imaging in mouse models of B cell lymphoma and its potential implementations. We aimed to develop [⁸⁹Zr]Zr-N-sucDf-NNV003 as a surrogate image tool for the assessment of [¹⁷⁷Lu]Lu-DOTA-NNV003 RIT whole-body distribution and tumor uptake. [⁸⁹Zr]Zr-N-sucDf-NNV003 pre-therapy PET imaging in patients with B cell NHL may help to identify those more likely to respond. Furthermore, as a surrogate imaging tool, [⁸⁹Zr]Zr-N-sucDf-NNV003 may aid in optimizing [¹⁷⁷Lu]Lu-DOTA-NNV003 RIT dose-regimens and post-therapy response evaluation.